Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Accumulated Expenses (2023 - 2025)

Compass Therapeutics' Accumulated Expenses history spans 3 years, with the latest figure at $11.4 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 81.06% year-over-year to $11.4 million; the TTM value through Dec 2025 reached $11.4 million, up 81.06%, while the annual FY2025 figure was $11.4 million, 81.06% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $11.4 million at Compass Therapeutics, up from $8.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $11.4 million in Q4 2025 and bottomed at $989000.0 in Q2 2023.
  • The 3-year median for Accumulated Expenses is $4.2 million (2023), against an average of $5.3 million.
  • The largest annual shift saw Accumulated Expenses crashed 79.7% in 2024 before it soared 375.02% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $1.9 million in 2023, then soared by 224.41% to $6.3 million in 2024, then surged by 81.06% to $11.4 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Accumulated Expenses are $11.4 million (Q4 2025), $8.7 million (Q3 2025), and $11.0 million (Q2 2025).